## Laeeq Malik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11747622/publications.pdf

Version: 2024-02-01

13 papers	161 citations	7 h-index	1199594 12 g-index
13	13	13	272 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Selective Targeting of Protein Kinase C (PKC)-Î, Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers. Cancers, 2022, 14, 1596.	3.7	3
2	Association between tyrosineâ€kinase inhibitor induced hypertension and treatment outcomes in metastatic renal cancer. Cancer Reports, 2020, 3, e1275.	1.4	6
3	Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch. Frontiers in Immunology, 2020, 11, 1228.	4.8	49
4	Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2019, 20, 3080.	4.1	15
5	Eligibility criteria for phase I clinical trials: tight vs loose?. Cancer Chemotherapy and Pharmacology, 2019, 83, 999-1002.	2.3	11
6	Increasing complexity in oncology phase I clinical trials. Investigational New Drugs, 2019, 37, 519-523.	2.6	9
7	Optimizing poly ( <scp>ADP</scp> â€ribose) polymerase inhibition through combined epigenetic and immunotherapy. Cancer Science, 2018, 109, 3383-3392.	3.9	28
8	A comparison of the quality of informed consent for phase I oncology trials over a 30-year period. Cancer Chemotherapy and Pharmacology, 2018, 82, 907-910.	2.3	5
9	Advanced Cancer Patients' Understanding and Perceptions of Phase I Clinical Trials. Cancer Investigation, 2015, 33, 490-495.	1.3	10
10	How well informed is the informed consent for cancer clinical trials?. Clinical Trials, 2014, 11, 686-688.	1.6	9
11	Predicting success in regulatory approval from Phase I results. Cancer Chemotherapy and Pharmacology, 2014, 74, 1099-1103.	2.3	9
12	Informed Consent for Phase I Oncology Trials: Form, Substance and Signature. Journal of Clinical Medicine Research, 2014, 6, 205-8.	1.2	5
13	A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED). Frontiers in Oncology, 0, 12, .	2.8	2